Navigation Links
BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
Date:9/4/2008

otide (MBP8298)

--------------------------

Dirucotide (MBP8298) is a synthetic peptide that consists of 17 amino acids having a sequence identical to that of a portion of human myelin basic protein (MBP). Dirucotide is being developed for the potential treatment of multiple sclerosis (MS), an autoimmune disease caused by immune attack against normal components of the central nervous system. The sequence of dirucotide is associated with the autoimmune process in MS patients with certain immune response genes (HLA types DR2 and/or DR4); MS patients having these genes represent 65 to 75 percent of all MS patients.

The drug's apparent mechanism of action is the induction or restoration of immunological tolerance with respect to ongoing immune attack as a result of high doses of peptide periodically delivered intravenously. The potential benefit of the drug for any individual patient is therefore expected to be related to the role this peptide plays in that patient's immune system. The degree of immunomodulation achieved will depend on the relationship among the peptide, HLA molecules and T cells.

The results of phase II and long-term follow-up treatment of MS patients with MBP8298 (dirucotide), published in 2006 in the European Journal of Neurology (EJN), showed that MBP8298 (dirucotide) safely delayed median time to disease progression for five years (versus placebo) in progressive MS patients with HLA types DR2 and/or DR4. Thus, dirucotide (MBP8298), if approved, has the potential to be used as a tailored therapy for patients genetically determined to express the appropriate HLA molecules.

Dirucotide (MBP8298) is being studied in four late-stage clinical trials:

- MAESTRO-01: A pivotal phase II/III trial for secondary progressive MS

(SPMS) patients in Canada and Europe.

- MAESTRO-02: An open-label safety extension study to MAESTRO-01.

- MAESTRO-03: A pivotal phase III trial for SPMS patients
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. BioMS Medical Announces Second Quarter 2008 Results
4. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
5. BioMS Medical to present at BMO Healthcare Conference
6. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medical to present at Jefferies Healthcare Conference
8. BioMS Medical to present at 2008 BIO International Convention
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical announces first quarter 2008 results
11. BioMs Medical to present at TIDES(R) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Marktech Optoelectronics has introduced ... violet emitters in the 280 nm wavelength range. This ... which range from 280nm to 405nm. These new devices ... as well as curing. Mark Campito, Marktech’s CEO states ... interest to manufacturers is that we offer it in ...
(Date:9/22/2014)... who were treated with a statin in the hospital ... likely to survive than those who were not, according ... . This study was conducted by the same researchers ... can improve survival in victims of ischemic stroke., Ischemic ... a blood vessel that blocks blood from reaching areas ...
(Date:9/22/2014)... cell fragments whose job it is to stop bleeding, ... But they can "feel" the physical environment around them, ... Platelets respond to surfaces with greater stiffness by increasing ... other platelets and other components of the clotting system, ... give them credit for, in that they are able ...
(Date:9/22/2014)... Lawrence Livermore National Laboratory Director Bill ... renewed their institutional commitment by signing a memorandum ... expand the collaborative work in the areas of ... and environmental sciences. , This renewal represents a ... December 2009 and is a framework to broaden ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2Statin use during hospitalization for hemorrhagic stroke associated with improved survival 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Lawrence Livermore Renews Pact with Georgetown University to Expand Research and Education in Science and Policy 2
... , ... , Formation of new blood ... been the focus of many drug screening and cell signaling research studies. Blood ... tumors, and is implicated in wound healing, retinopathy and macular degeneration. , ...
... , Tran T. Nham Varian Australia ... Introduction , Because ... with an ICP spectrometer, it has been widely used to determine trace ... work was to evaluate the ability of the ultrasonic nebulizer to handle ...
... Varian, Inc. , Introduction ... are veterinary drugs. The use of these in food production is ... and the European Union because of a possible increased cancer-risk through ... of nitrofurans contamination has been found in warm-water prawns, shrimp, and ...
Cached Biology Technology:An Image-Based Assay of Endothelial Cell Tube Formation as a Model of Angiogenesis 2An Image-Based Assay of Endothelial Cell Tube Formation as a Model of Angiogenesis 3An Image-Based Assay of Endothelial Cell Tube Formation as a Model of Angiogenesis 4Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 2Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 3Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer 4Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS 2
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... insects to predict how climate change will affect their ... the first time that insects, fear of their predators, ... grow. , "In other words, it,s less about temperature ... the growth, survival and distribution of insects." says the ... postdoctoral researcher at Dartmouth. , The study ...
(Date:9/23/2014)... that the Company has secured $21 million in a ... to expand the Company,s cancer immunotherapy pipeline and advance ... Capital led the round, with participation from Majuven and ... Venture and Harbinger Venture Capital. , Eureka is ... engineered to mimic the functions of a T cell ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... countertop, a practiced eye and Google Earth all ... of fossils that may shed light on the ... serendipitous story, featuring University of Michigan paleontologists Philip ... subject of a segment on the award-winning television ...
... UC Riverside,s Alexander Raikhel , a professor of ... Academy of Sciences (NAS) for his excellence in original ... one of the highest honors given to a scientist or ... into the academy next April during its 147th annual meeting ...
... State University today announced the discovery of a genetic regulator ... types of head and neck cancers, in work that may ... therapy at some point in the future. This ... been demonstrated to be a master regulator that has important ...
Cached Biology News:Google Earth aids discovery of early African mammal fossils 2Google Earth aids discovery of early African mammal fossils 3UC Riverside professor receives top scientific honor 2UC Riverside professor receives top scientific honor 3New diagnostic advance seen for head, throat cancer 2
ANXA11 Immunogen: ANXA11 (NP_001148, 406 a.a. ~ 506 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Anti-ADAM-12 (Meltrin Alpha); carboxy terminal end; rabbit host...
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to CHMP5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-NKDGVLVDEFGLPQ, corresponding to C terminal amino acids 202-215 of Human CHMP5 Entrez GeneID: ...
Biology Products: